{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T14:34:04Z","timestamp":1787841244721,"version":"build-2784847793"},"reference-count":10,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:p>Myocarditis attributable to immune checkpoint inhibitors is regarded as among the most serious complications of immunotherapeutic treatment. We report a case of gastric cancer who developed myocarditis, and subsequent late complications following treatment with nivolumab and ipilimumab. The patient was managed with corticosteroids, mycophenolate mofetil (MMF), and intravenous immunoglobulin G (IVIG), but later developed supraventricular tachycardia and deep vein thrombosis. This report emphasizes the need to enhance recognition of immune-related toxicities within non-oncology specialties to support prompt interdisciplinary collaboration and appropriate patient management. Additionally, patients can develop myocarditis-related complications even when clinically stable or near the end of treatment, underscoring the need for close and ongoing monitoring.<\/jats:p>","DOI":"10.4103\/njcp.njcp_692_25","type":"journal-article","created":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T03:00:13Z","timestamp":1774926013000},"page":"356-359","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Severe Myocarditis after Nivolumab and Ipilimumab in a Patient with Microsatellite Instability-High Gastric Adenocarcinoma: A Case Report"],"prefix":"10.4103","volume":"29","author":[{"given":"S","family":"Tun\u00e7","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Harran University Faculty of Medicine, Haliliye\/\u015eanl\u0131urfa, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O","family":"Karhan","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Harran University Faculty of Medicine, Haliliye\/\u015eanl\u0131urfa, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Ko\u00e7","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Harran University Faculty of Medicine, Haliliye\/\u015eanl\u0131urfa, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,3,31]]},"reference":[{"key":"R1-20260416","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s11886-021-01440-3","article-title":"Immunotherapy-associated cardiotoxicity of \u0131mmune checkpoint \u0131nhibitors and chimeric antigen receptor T cell therapy: Diagnostic and management challenges and strategies","volume":"23","author":"Stein-Merlob","year":"2021","journal-title":"Curr Cardiol Rep"},{"key":"R2-20260416","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with \u0131mmune checkpoint \u0131nhibitors: A systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"key":"R3-20260416","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1161\/CIRCULATIONAHA.119.042276","article-title":"Cardio-\u0131mmuno-oncology","volume":"141","author":"Zaha","year":"2020","journal-title":"Circulation"},{"key":"R4-20260416","doi-asserted-by":"crossref","first-page":"112385","DOI":"10.1016\/j.intimp.2024.112385","article-title":"Prognosis of immune checkpoint inhibitor-related myocarditis: Retrospective experience of a single institution","volume":"136","author":"Qin","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"R5-20260416","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1093\/eurheartj\/ehab674","article-title":"Defining cardiovascular toxicities of cancer therapies: An International Cardio-Oncology Society (IC-OS) consensus statement","volume":"43","author":"Herrmann","year":"2022","journal-title":"Eur Heart J"},{"key":"R6-20260416","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of \u0131mmune-related adverse events in patients treated with \u0131mmune checkpoint \u0131nhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol"},{"key":"R7-20260416","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1161\/CIRCULATIONAHA.119.044703","article-title":"Major adverse cardiovascular events and the timing and dose of corticosteroids in \u0131mmune checkpoint \u0131nhibitor-associated myocarditis","volume":"141","author":"Zhang","year":"2020","journal-title":"Circulation"},{"issue":"6_Supplement","key":"R8-20260416","doi-asserted-by":"crossref","first-page":"2480","DOI":"10.1158\/1538-7445.AM2024-2480","article-title":"Treatment of steroid-refractory immune checkpoint inhibitor-associated myocarditis: A case series of 18 patients","volume":"84","author":"Jayakrishnan","year":"2024","journal-title":"Cancer Res"},{"key":"R9-20260416","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.3390\/diagnostics13071243","article-title":"Immune checkpoint \u0131nhibitors-related myocarditis: A review of reported clinical cases","volume":"13","author":"Zotova","year":"2023","journal-title":"Diagnostics (Basel)"},{"key":"R10-20260416","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1161\/CIRCULATIONAHA.121.055816","article-title":"Electrocardiographic manifestations of \u0131mmune checkpoint \u0131nhibitor myocarditis","volume":"144","author":"Power","year":"2021","journal-title":"Circulation"}],"container-title":["Nigerian Journal of Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/njcp.njcp_692_25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:47:20Z","timestamp":1787838440000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/njcp.njcp_692_25"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":10,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.4103\/njcp.njcp_692_25","relation":{},"ISSN":["1119-3077","2229-7731"],"issn-type":[{"value":"1119-3077","type":"print"},{"value":"2229-7731","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"2025-10-10","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-19","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}